BR112016030096A8 - composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina - Google Patents
composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacinaInfo
- Publication number
- BR112016030096A8 BR112016030096A8 BR112016030096A BR112016030096A BR112016030096A8 BR 112016030096 A8 BR112016030096 A8 BR 112016030096A8 BR 112016030096 A BR112016030096 A BR 112016030096A BR 112016030096 A BR112016030096 A BR 112016030096A BR 112016030096 A8 BR112016030096 A8 BR 112016030096A8
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine
- immunogenic composition
- protein
- cdtb
- modify
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 6
- 229960005486 vaccine Drugs 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108010010925 Clostridium actin-specific ADP-ribosyltransferase Proteins 0.000 abstract 2
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina. a presente invenção refere-se a composições imunogênicas que compreendem cdtb de clostridium difficile isolado. em particular, a proteína de cdtb de clostridium difficile isolada foi mutada para modificar a capacidade de formação de poros, para modificar a capacidade de heptamerização ou é uma proteína de cdtb truncada com o peptídeo de sinal e o pró-domínio removido e também o domínio de ligação ao receptor removido e/ou o domínio de ligação de cdta removido. a invenção também se refere a proteínas de fusão compreendendo uma proteína de cdta e uma proteína de cdtb. as vacinas compreendendo tais composições imunogênicas e usos terapêuticos das mesmas também fazem parte da invenção.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1411306.2A GB201411306D0 (en) | 2014-06-25 | 2014-06-25 | Immunogenic composition |
| GB1411306.2 | 2014-06-25 | ||
| GB1411371.6 | 2014-06-26 | ||
| GB201411371A GB201411371D0 (en) | 2014-06-26 | 2014-06-26 | Immunogenic composition |
| PCT/EP2015/064324 WO2015197737A1 (en) | 2014-06-25 | 2015-06-25 | Clostridium difficile immunogenic composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112016030096A2 BR112016030096A2 (pt) | 2017-08-22 |
| BR112016030096A8 true BR112016030096A8 (pt) | 2021-07-06 |
| BR112016030096B1 BR112016030096B1 (pt) | 2023-10-03 |
Family
ID=53498986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016030096-3A BR112016030096B1 (pt) | 2014-06-25 | 2015-06-25 | Composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20170218031A1 (pt) |
| EP (2) | EP3160500B1 (pt) |
| JP (2) | JP6688233B2 (pt) |
| CN (1) | CN106536544B (pt) |
| BE (1) | BE1022949B1 (pt) |
| BR (1) | BR112016030096B1 (pt) |
| CA (1) | CA2952118A1 (pt) |
| CY (1) | CY1122145T1 (pt) |
| DK (1) | DK3160500T3 (pt) |
| ES (1) | ES2749701T3 (pt) |
| HR (1) | HRP20191864T1 (pt) |
| HU (1) | HUE045936T2 (pt) |
| LT (1) | LT3160500T (pt) |
| MX (1) | MX2016017094A (pt) |
| PL (1) | PL3160500T3 (pt) |
| PT (1) | PT3160500T (pt) |
| SI (1) | SI3160500T1 (pt) |
| WO (1) | WO2015197737A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3595709A4 (en) * | 2017-03-15 | 2020-12-23 | Novavax, Inc. | METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES TO CLOSTRIDIUM DIFFICILE |
| CN112703006A (zh) | 2018-06-19 | 2021-04-23 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| EP0362278A4 (en) | 1987-06-05 | 1990-05-14 | Us Health | FACTORS OF AUTOCRINE MOTILITY IN THE DIAGNOSIS AND TREATMENT OF CANCER. |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ATE115862T1 (de) | 1989-02-04 | 1995-01-15 | Akzo Nobel Nv | Tocole als impfstoffadjuvans. |
| PL170980B1 (pl) | 1992-06-25 | 1997-02-28 | Smithkline Beecham Biolog | Szczepionka PL PL PL PL PL PL PL |
| ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| NZ295998A (en) | 1994-10-24 | 1999-10-28 | Ophidian Pharm Inc | Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| EP0832282A1 (en) | 1995-06-02 | 1998-04-01 | Incyte Pharmaceuticals, Inc. | IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES |
| JP2002542169A (ja) * | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| US20020065396A1 (en) | 2000-03-28 | 2002-05-30 | Fei Yang | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| WO2005004791A2 (en) * | 2002-11-08 | 2005-01-20 | President And Fellows Of Harvard College | Compounds and methods for the treatment and prevention of bacterial infection |
| AU2012349753A1 (en) * | 2011-12-08 | 2014-06-19 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| SI2928489T1 (sl) * | 2012-12-05 | 2019-05-31 | Glaxosmithkline Biologicals S.A. | Imunogeni sestavek |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
-
2015
- 2015-06-25 CN CN201580039744.7A patent/CN106536544B/zh active Active
- 2015-06-25 ES ES15733404T patent/ES2749701T3/es active Active
- 2015-06-25 JP JP2016575190A patent/JP6688233B2/ja active Active
- 2015-06-25 HU HUE15733404A patent/HUE045936T2/hu unknown
- 2015-06-25 EP EP15733404.6A patent/EP3160500B1/en active Active
- 2015-06-25 LT LT15733404T patent/LT3160500T/lt unknown
- 2015-06-25 EP EP19192151.9A patent/EP3636278A3/en not_active Withdrawn
- 2015-06-25 BE BE2015/5390A patent/BE1022949B1/fr active
- 2015-06-25 BR BR112016030096-3A patent/BR112016030096B1/pt active IP Right Grant
- 2015-06-25 WO PCT/EP2015/064324 patent/WO2015197737A1/en active Application Filing
- 2015-06-25 US US15/320,190 patent/US20170218031A1/en not_active Abandoned
- 2015-06-25 SI SI201530954T patent/SI3160500T1/sl unknown
- 2015-06-25 MX MX2016017094A patent/MX2016017094A/es active IP Right Grant
- 2015-06-25 PT PT157334046T patent/PT3160500T/pt unknown
- 2015-06-25 DK DK15733404T patent/DK3160500T3/da active
- 2015-06-25 PL PL15733404T patent/PL3160500T3/pl unknown
- 2015-06-25 CA CA2952118A patent/CA2952118A1/en active Pending
-
2019
- 2019-10-09 CY CY20191101061T patent/CY1122145T1/el unknown
- 2019-10-15 HR HRP20191864TT patent/HRP20191864T1/hr unknown
-
2020
- 2020-01-17 JP JP2020005532A patent/JP2020100625A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BE1022949B1 (fr) | 2016-10-21 |
| JP6688233B2 (ja) | 2020-04-28 |
| CA2952118A1 (en) | 2015-12-30 |
| PL3160500T3 (pl) | 2020-02-28 |
| EP3160500A1 (en) | 2017-05-03 |
| BE1022949A1 (fr) | 2016-10-21 |
| ES2749701T3 (es) | 2020-03-23 |
| BR112016030096A2 (pt) | 2017-08-22 |
| EP3636278A2 (en) | 2020-04-15 |
| EP3160500B1 (en) | 2019-08-21 |
| MX2016017094A (es) | 2017-05-03 |
| WO2015197737A1 (en) | 2015-12-30 |
| US20170218031A1 (en) | 2017-08-03 |
| LT3160500T (lt) | 2019-10-25 |
| HRP20191864T1 (hr) | 2020-01-10 |
| JP2020100625A (ja) | 2020-07-02 |
| PT3160500T (pt) | 2019-11-11 |
| CN106536544A (zh) | 2017-03-22 |
| CN106536544B (zh) | 2020-04-07 |
| JP2017520573A (ja) | 2017-07-27 |
| EP3636278A3 (en) | 2020-07-15 |
| DK3160500T3 (da) | 2019-11-11 |
| HUE045936T2 (hu) | 2020-01-28 |
| CY1122145T1 (el) | 2020-11-25 |
| SI3160500T1 (sl) | 2019-11-29 |
| BR112016030096B1 (pt) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017010088A2 (pt) | polinucleotídeo modulatório, pré-micro-rna artificial, vírus recombinante de aav, composição compreendendo o plasmídeo ou vetor, kit compreendendo o referido plasmídeo ou vetor e uso do mesmo | |
| DK3570879T3 (da) | Immunogene sammensætninger til anvendelse i pneumokokvacciner | |
| BR112016022814A8 (pt) | composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico | |
| DK3244917T3 (da) | Immunogene sammensætninger til anvendelse i pneumokokvacciner | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
| BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
| BR112016028066A2 (pt) | composição de vacina; idessuis; ridessuis; anticorpo; composição parenteral; uso de uma proteína idessuis ou ridessuis; e célula hospedeira | |
| AR105470A1 (es) | Métodos para inducir una respuesta inmune | |
| BR112016030577A2 (pt) | vacinas contra o vírus da gripe e usos das mesmas | |
| BR112016022062A2 (pt) | Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico | |
| BR112018071466A2 (pt) | novos peptídeos de ligação a cd1d imunogênicos | |
| BR112019012796A2 (pt) | proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas | |
| BR112016019735A2 (pt) | fhbp, polipeptídeo, plasmídeo ou outro ácido nucleico, célula hospedeira, vesículas de membrana, e, composição imunogênica | |
| BR112016027595A8 (pt) | produtos de peptídeos, composição farmacêutica compreendendo um produto de peptídeo, uso de um produto de peptídeo e método para produzir um produto de peptídeo | |
| BR112015025748A2 (pt) | construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna | |
| BR112015014727B8 (pt) | Composição imunogênica, vacina, e, uso de uma composição imunogênica | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| BR112016029013A2 (pt) | aperfeiçoamento em composição nasal e método de utilização do mesmo | |
| IL275435A (en) | TATK – CDKL5 fusion proteins, preparations, formulations, and their uses | |
| EP3193919A4 (en) | Immunogenic/therapeutic glycoconjugate compositions and uses thereof | |
| BR112019010128A2 (pt) | proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas | |
| DK3146042T3 (da) | Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop | |
| BR112015023738B8 (pt) | Vacinas de nucleoproteina influenza | |
| BR112016030096A8 (pt) | composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/06/2015, OBSERVADAS AS CONDICOES LEGAIS |